U.S. Markets closed
  • S&P 500

    3,900.11
    -11.63 (-0.30%)
     
  • Dow 30

    31,438.26
    -62.42 (-0.20%)
     
  • Nasdaq

    11,524.55
    -83.07 (-0.72%)
     
  • Russell 2000

    1,771.74
    +6.01 (+0.34%)
     
  • Crude Oil

    109.81
    +0.24 (+0.22%)
     
  • Gold

    1,824.00
    -0.80 (-0.04%)
     
  • Silver

    21.17
    -0.00 (-0.01%)
     
  • EUR/USD

    1.0588
    +0.0029 (+0.2753%)
     
  • 10-Yr Bond

    3.1940
    +0.0690 (+2.21%)
     
  • Vix

    26.95
    -0.28 (-1.03%)
     
  • GBP/USD

    1.2270
    +0.0000 (+0.0012%)
     
  • USD/JPY

    135.3910
    +0.2210 (+0.1635%)
     
  • BTC-USD

    20,814.13
    -552.04 (-2.58%)
     
  • CMC Crypto 200

    455.80
    -6.00 (-1.30%)
     
  • FTSE 100

    7,258.32
    +49.51 (+0.69%)
     
  • Nikkei 225

    26,871.27
    +379.30 (+1.43%)
     

bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., January 05, 2022--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the virtual 40th Annual J.P. Morgan Healthcare Conference, Wednesday, January 12, at 3:45 p.m. ET.

To access the live webcast of bluebird bio’s presentation, please visit the "Events & Presentations" page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 30 days following the event.

About bluebird bio, Inc.

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

With a dedicated focus on severe genetic diseases, bluebird has industry-leading clinical and research programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. ​

For more information, visit bluebirdbio.com or follow us on social media at @bluebirdbio, LinkedIn, Instagram and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005622/en/

Contacts

Investors:
Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com
or
Media:
Sarah Alspach, 857-299-6198
sarah.alspach@bluebirdbio.com